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List of abbreviations: 
BEV: animals, treated with bevacizumab (45mg/kg) 
CNS: central nervous system 
CTR: control group, animals receiving saline only 
DEX 12: animals treated with dexamethasone (12mg/kg/day) 
DEX 2: animals treated with dexamethasone (2mg/kg/day) 
DSC: dynamic susceptibility contrast 
GBCA: gadolinium based contrast agent 
GBM: glioblastoma 
IF: impact factor 
MR(I): magnetic resonance (imaging) 
MRA: magnetic resonance angiography 
PWI: perfusion weighted imaging 
rCBV: relative cerebral blood volume 
rMTT: relative mean transit time 
ROI: region of interest 
T: tesla 
T1w: T1-weighted 
TOF: time of flight 
TTP: time to peak 
USPIO: ultrasmall superparamagnetic iron oxide 
VEGF: vascular endothelial growth factor 
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1  INTRODUCTION 
 
High-grade gliomas such as glioblastoma (GBM), anaplastic 
astrocytoma, and anaplastic oligodendroglioma are commonly 
treated with radiation therapy with concomitant temozolomide 
chemotherapy, followed by adjuvant temozolomide. In addition, at 
recurrence, as a second line therapy patients may receive anti-
angiogenic therapy such as bevacizumab (Avastin®), a monoclonal 
antibody against vascular endothelial growth factor (VEGF). Tumor 
response is generally determined using the Macdonald treatment 
response criteria, which is based on post-contrast tumor enhancement 
on T1-weighted (T1w) magnetic resonance (MR) images. Decreases 
in tumor vascular permeability and normalization of existing tumor 
vasculature after bevacizumab treatment can be interpreted as 
decreased tumor volume and apparent tumor response; however, 
tumor progression as non-enhancing or infiltrative disease can occur 
in bevacizumab-treated patients. Bevacizumab-induced 
pseudoresponse, also referred to as pseudoregression, makes 
radiographic responses challenging to interpret. Similarly, increasing 
tumor vascular permeability during and after radiotherapy can result 
in an increasing contrast enhancement, without an increase of the 
underlying tumor mass, this called pseudoprogression. Both pseudo-
phenomena confuse the assessment of outcome of brain tumors in 
clinical practice and in clinical trials. To overcome these issues, 
alternative endpoints and response criteria are needed.   
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My PhD thesis deals with an MR contrast agent, an ultrasmall 
superparamagnetic iron oxide (USPIO) compound, called 
ferumoxytol and its application in high grade primary malignant 
brain tumors. The ultimate goal of these research projects is a 
“better” detection of brain malignancies, including improved 
specificity and sensitivity, and the evaluation of early therapeutic 
changes, overcoming the above mentioned issues with therapy 
assessment, and thus to help find the optimal therapeutic options. 
Besides anatomical imaging, the main interest of my research is 
dynamic MR imaging, especially the dynamic susceptibility contrast 
(DSC) perfusion weighted imaging (PWI), by taking advantage of 
two important properties of ferumoxytol, such as: no substantial 
extravasation during the first pass, and a strong T2* shortening 
effect.  
 
In this writing two studies, one clinical and one preclinical, will be 
detailed in this unusual order. The clinical part is mainly 
concentrating on anatomical imaging, whereas the preclinical part 
uses more advanced imaging techniques, and aims to detect early 
therapeutic changes during antiangiogenic therapy. Therefore the 
clinical part will be discussed first.  
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2  OBJECTIVES 
2.1 Clinical studies:   
Ferumxytol has not been used before as an imaging agent in the 
central nervous system (CNS) in patients. The clinical objective of 
my work was to investigate the potential for this USPIO as an MR 
contrast agent in CNS malignancies:  
1. Evaluation of enhancement time course in patients, and 
comparison with standard gadolinium based contrast agent 
(GBCA) enhancement on T1w scans. 
2. Assessing the utility of ferumoxytol in various MR imaging 
techniques, including time of flight (TOF) MR angiography 
(MRA) and PWI, using the DSC technique.  
3. Comparison of MR imaging using ferumoxytol at various 
magnetic field strengths. 
 
2.2 Preclinical studies: 
The preclinical studies were carried out on a 12 tesla experimental 
MR system with the following objectives: 
4. To develop a study protocol, including an intracranial tumor 
model in rats, and serial dynamic MR imaging on 12T using a 
standardized bolus injection of ferumoxytol and GBCA. 
5. Comparison of DSC imaging using ferumoxytol vs. GBCA. 
6. Detection of early therapeutic changes of the antiangiogenic 
drug, bevacizumab, using a dual agent MR imaging method 
(ferumoxytol for perfusion assessment and GBCA for 
permeability estimation) 
5 
 
3  METHODS 
3.1 Clinical studies 
Twelve patients with malignant brain tumors underwent serial 
magnetic resonance imaging multiple times up to 72 hours after 
ferumoxytol injection at both 1.5 and 3T. The enhancement time 
course of this long circulating agent (plasma half life 14-21h) was 
determined at each magnetic field strength. Ferumoxytol 
enhancement was also compared with a baseline GBCA enhanced 
scan. Perfusion parametric maps, TOF MRA and quantitative T1-
measurement were compared for the two agents. Region of interest 
(ROI) based analysis was performed for relative cerebral blood 
volume (rCBV), relative mean transit time (rMTT) and changes in 
T1 values in the enhancing tumor and in the surrounding area.  
 
3.2 Preclinical Studies 
Athymic rats with intracerebral U87 human glioma were used to test 
dynamic MR imaging at 12T. To compare ferumoxytol and 
gadodiamide in DSC imaging, two animals underwent DSC imaging 
with gadodiamide and one day later with ferumoxytol. In the tumoral 
ROI Time-Intensity curves were analyzed and rCBV was estimated 
and compared between the two agents. In the second half of the 
study we used serial dynamic contrast-enhanced MRI to assess early 
vascular responses to antiangiogenic versus steroid therapy. Tumor 
bearing rats (n=17) underwent DSC perfusion MRI with 
ferumoxytol, followed by T1w dynamic contrast enhanced (DCE) 
MRI using gadodiamide to measure vascular permeability. Rats were 
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imaged before and after 24, 48, and 72h of treatment with the 
antiangiogenic agent bevacizumab, the corticosteroid dexamethasone 
(in two different doses) or saline as controls, thus resulting four 
treatment groups. Treatment groups: BEV: bevacizumab (45mg/kg) 
n=5; DEX-2: dexamethasone (2mg/kg per day) n=4, DEX-12: 
dexamethasone (12mg/kg per day) n=5; and CTR: control n=3. 
rCBV values of the tumors were calculated using the DSC perfusion 
series on a ROI basis. DCE scans were processed by defining the 
time to peak (TTP) enhancement in the tumor. Changes in rCBV and 
TTP enhancement were statistically analyzed throughout the study 
using repeated measurements of two-way analysis of variance with 
Tukey’s post hoc statistical test. P < 0.05 was considered significant.  
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4  RESULTS AND DISCUSSION 
4.1 Clinical Studies 
Using ferumoxytol, contrast enhancement was detectable in all the 
studied patients at all magnetic field strengths, even with a low field 
intraoperative 0.15-T magnet. Maximal ferumoxytol enhancement 
intensity was detected at 24 to 28 hours after administration, and the 
enhancing volume subsequently expanded with time into a non-
gadolinium-enhancing, surrounding T2-hyperintense region. The 
enhancement appeared to be more intense at 1.5T than on 3T. In 
most cases ferumoxytol enhancement was less intense than GBCA 
enhancement. Differences in enhancement patterns of ferumoxytol 
vs. GBCA agents could be also explained with slightly different 
mechanism of extravasation, and also the uptake of ferumoxytol by 
inflammatory cells within and around the tumor mass may play an 
important role. DSC studies were assessed with both agents. In 
tumors with high vascular permeability, the early vascular leakage of 
GBCA overestimated the rCBV. This was only found with 
gadolinium but not with ferumoxytol. Nevertheless there was no 
significant difference in rCBV or rMTT values between the two 
agents when comparing in the entire study population. TOF MRA 
post contrast administration depicted more blood vessels with either 
contrast agents, without visible extravasation when ferumoxytol was 
used. T1 values in GBCA enhancing tumor regions did not show 
significant changes post ferumoxytol injection confirming that 
ferumoxytol stays intravascular early after contrast agent 
administration. These results confirmed that ferumoxytol stays 
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intravascular in the early phase, which could be exploited to assess 
the micro and macro vasculature.  
 
4.2 Preclinical Studies 
The U87 tumor model was found to be a suitable intracranial model 
to test DSC perfusion measurement. Contrast agent extravasation 
was seen rapidly after gadodiamide resulting a substantial 
underestimation of rCBV in this tumor model. This was not found 
with ferumoxytol. The dual agent imaging method could be 
successfully applied with only a minimal confounding effect, alone 
the arterial input function could not be measured due to high 
concentration intravascular iron oxide particles. The ferumoxytol 
bolus was suitable for rCBV measurement, followed by gadodiamide 
injection, in which the dynamics of parenchymal enhancement could 
be used to test the vascular permeability expressed as TTP 
enhancement.  
Evaluating early therapeutic response, both of these measures 
showed significant early changes (Figure 1): In the BEV group, the 
initial rCBV (1.628±0.091) (means±s.e.m.) decreased significantly in 
all 24, 48, and 72h time points to 1.214±0.061, 1.082±0.064, and 
1.084±0.052, respectively (Figure 1A). In the DEX 2 group, the 
initial rCBV of 2.130±0.180 showed significant decrease in the 48 
and 72 h time points (1.755±0.040 and 1.725±0.098, respectively). In 
the DEX 12 group, the initial 1.800±0.072 rCBV value decreased 
significantly at all time points, to 1.380±0.029 at 24 h, 1.286±0.028 
at 48 h, and 1.272±0.041 at 72 h. In the CTR group, there was no 
significant change found from the initial 1.927±0.363 rCBV value.  
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Comparing the treatment groups the normalized rCBV in BEV and 
DEX 12 groups appeared to be significantly decreased compared 
with the CTR and DEX 2 groups in all the three post treatment time 
points. The difference between the BEV and DEX 12 groups was not 
significant. The DEX 2 group became significantly different from 
the CTR group at the 48 and 72 h time points.  
Changes in vascular permeability were following (Figure 1B): In the 
BEV group, the initial TTP of 60±19s increased significantly in all 
24, 48, and 72 h post treatment time points to 125±42s, 176±50s, and 
194±58s, respectively). Similarly, in the DEX 12 group, the initial 
62±14 secs increased to 107±27s, 127±41s, and 133±44s, 
respectively. The baseline TTP of 72±17s in the DEX 2 group and 
the 58±12s in the control group has not shown significant changes 
throughout the study.  
After normalizing the TTP data to the pretreatment value in each 
treatment group, there was no significant difference between the 
groups 24 h after the start of treatment. At the 48 h time point in the 
BEV treatment group, the TTP increased significantly to 3.023±0.58 
compared with the CTR (1.071±0.05) and also compared with the 
DEX 2 TTP (1.517±0.25), but it was not significantly different from 
DEX 12 (1.907±0.16, P = 0.051). At 72 h post-treatment time point, 
the normalized TTP in the BEV group increased to 3.313±0.59, and 
was found to be significantly higher than that in all the three other 
groups (CTR: 1.110±0.06, DEX 2: 1.581±0.37, and DEX 12: 
2.064±0.34). There were no other significant differences between 
groups. 
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Figure 1 Early rCBV (A) and TTP (B) changes after treatment.  
* indicates significance (p<0.05) 
A 
B 
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5  CONCLUSIONS 
 
Ferumoxytol, a bolus injectable USPIO may serve as a 
complimentary MR contrast agent to improve localization, 
characterization, and follow-up in CNS malignancies. Using DSC 
perfusion, it will be invaluable in the future for monitoring 
therapeutic responses to antiangiogenic chemotherapies. 
Ferumoxytol, in particular, is an exciting and powerful tool that is 
approved by the United States Food and Drug Administration and 
can be used to study a variety of CNS pathologies. We conclude that 
dynamic perfusion MRI measurement with ferumoxytol USPIO to 
assess cerebral blood volume, along with dynamic gadodiamide-
enhanced MR to assess vascular permeability in the same imaging 
session is feasible, and holds promise in more accurately detecting 
therapeutic responses to antiangiogenic therapy. In our preclinical 
study a dramatic rCBV and permeability decrease was observed as 
early as 24h post treatment. These findings were similar, but more 
pronounced compared to high doses of corticosteroids.  
This work is a step forward in tumor treatment response assessment 
using advanced dynamic MR imaging techniques, which may 
complement the currently used, mainly contrast enhancement based 
response criteria. These results may help solving diagnostic problems 
of pseudoresponse and pseudoprogression, which is one of our most 
relevant future directions. 
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6  NEW SCIENTIFIC RESULTS 
6.1 Clinical studies 
1. Ferumoxytol can be used as an MR contrast agent in CNS 
malignancies. Enhancement intensity peaks around 24 hours 
after intravenous administration. In most cases enhancement on 
T1w scans is somewhat less intense than at GBCA. 
2. In early time points ferumoxytol remains intravascular, and the 
vasculature can be depicted by TOF MRA, without confounding 
effect of contrast extravasation. The bolus injectable 
ferumoxytol is suitable for DSC perfusion measurement.  
3. Unlike GBCA, ferumoxytol enhancement on T1w scans shows a 
higher intensity at lower magnetic field strength.  
 
6.2 Preclinical studies 
4. Dual agent imaging with ferumoxytol followed by GBCA can 
be beneficial to evaluate the contrast agent leakage and also the 
rCBV with minimal confounding effect in the same imaging 
session. 
5. The U87 tumor model is highly permeable for GBCA, but not 
for ferumoxytol. Using USPIO, the misinterpretation of rCBV 
derived from contrast agent extravasation can be prevented. 
6. Bevacizumab treatment causes a rapid decrease in both tumor 
rCBV and also blood brain barrier permeability. This effect is 
similar to a high dose corticosteroid treatment. 
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